393 related articles for article (PubMed ID: 9178834)
1. Purine analogs in the treatment of chronic lymphocytic leukemia.
Pott C; Hiddemann W
Leukemia; 1997 Apr; 11 Suppl 2():S25-8. PubMed ID: 9178834
[TBL] [Abstract][Full Text] [Related]
2. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features.
Morabito F; Stelitano C; Callea I; Filangeri M; Oliva B; Sculli G; Callea V; Nobile F; Brugiatelli M
Haematologica; 1996; 81(3):224-31. PubMed ID: 8767527
[TBL] [Abstract][Full Text] [Related]
3. Present status of purine analogs in the therapy of chronic lymphocytic leukemias.
Bergmann L
Leukemia; 1997 Apr; 11 Suppl 2():S29-34. PubMed ID: 9178835
[TBL] [Abstract][Full Text] [Related]
4. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
5. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.
Nabhan C; Gartenhaus RB; Tallman MS
Leuk Res; 2004 May; 28(5):429-42. PubMed ID: 15068894
[TBL] [Abstract][Full Text] [Related]
6. Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
Mulligan SP; Karlsson K; Strömberg M; Jønsson V; Gill D; Hammerström J; Hertzberg M; McLennan R; Uggla B; Norman J; Wallvik J; Sundström G; Johansson H; Brandberg Y; Liliemark J; Juliusson G;
Leuk Lymphoma; 2014 Dec; 55(12):2769-77. PubMed ID: 24524339
[TBL] [Abstract][Full Text] [Related]
7. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases.
Stelitano C; Morabito F; Kropp MG; Callea V; Iuliano F; Oriana V; Levato D; Nobile F; Molica S; Brugiatelli M
Haematologica; 1999 Apr; 84(4):317-23. PubMed ID: 10190945
[TBL] [Abstract][Full Text] [Related]
9. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
Robak T
Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
[TBL] [Abstract][Full Text] [Related]
10. Current results and prospective trials of cladribine in chronic lymphocytic leukemia.
Tallman MS; Hakimian D
Semin Hematol; 1996 Jan; 33(1 Suppl 1):23-7. PubMed ID: 8714613
[No Abstract] [Full Text] [Related]
11. Therapy for previously untreated chronic lymphocytic leukemia: a reevaluation.
Cheson BD
Semin Hematol; 1998 Jul; 35(3 Suppl 3):14-21. PubMed ID: 9685175
[No Abstract] [Full Text] [Related]
12. Is there a place for 2-CDA in the treatment of B-CLL?
Mitterbauer M; Hilgenfeld E; Wilfing A; Jäger U; Knauf WU
Leukemia; 1997 Apr; 11 Suppl 2():S35-7. PubMed ID: 9178836
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of chronic lymphatic leukemia].
Adam Z; Vorlícek J; Hejlová N
Vnitr Lek; 1996 Aug; 42(8):573-8. PubMed ID: 8967031
[TBL] [Abstract][Full Text] [Related]
14. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia.
Robak T; Kasznicki M
Leukemia; 2002 Jun; 16(6):1015-27. PubMed ID: 12040433
[TBL] [Abstract][Full Text] [Related]
15. 2-Chlorodeoxyadenosine (2-CdA) in chronic lymphocytic leukemia refractory to fludarabine?
Schirmer M; Michlmayr G; Geisen F; Konwalinka G
Leukemia; 1996 Jul; 10(7):1253-4. PubMed ID: 8684013
[No Abstract] [Full Text] [Related]
16. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
Robak T
Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C
Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
[TBL] [Abstract][Full Text] [Related]
18. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
O'Brien S; Kantarjian H; Estey E; Koller C; Robertson B; Beran M; Andreeff M; Pierce S; Keating M
N Engl J Med; 1994 Feb; 330(5):319-22. PubMed ID: 7904047
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
[TBL] [Abstract][Full Text] [Related]
20. New purine analogues for the treatment of chronic B-cell malignancies.
Gribbin TE
Henry Ford Hosp Med J; 1991; 39(2):98-102. PubMed ID: 1679757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]